Clinical trials: Solid Tumors, completed
Advanced Colorectal Cancer
Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors
Curcumin is an extract of the tumeric root that has been shown to have anti-tumor properties in laboratory studies. Curcumin, and its parent spice, turmeric (curcuma longa), are the 4th most commonly purchased dietary supplement…
- Trial name
- NCT01859858
- Testing
- curcumin, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Solid Tumors
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors
Primary Objectives: To determine the maximum tolerated dose (MTD) of Topotecan when added to a fixed dose regimen of Ifosfamide and Carboplatin in children and young adults with solid tumors.
- Trial name
- NCT00502892
- Testing
- Topotecan, Ifosfamide, Carboplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Neoplasm
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).
- Trial name
- NCT03330106
- Testing
- Pevonedistat, Docetaxel, Carboplatin
- Where
- 8 sites in United States
- Volunteers
- 68 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine
RATIONALE: Educating health providers on talking with cancer patients about complementary and alternative medicine (CAM) may help encourage health providers to talk more often with cancer patients about the use of CAM.
- Trial name
- NCT00608933
- Testing
- educational intervention, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 1,356 people
- Sponsor
- M.D. Anderson Cancer Center
Safety Issues, Tolerability
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single…
- Conditions
- Safety Issues, Tolerability, Pharmacokinetics
- Trial name
- NCT05142592
- Testing
- IPG7236
- Where
- 7 sites in United States, China
- Volunteers
- 34 people
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Solid Tumors and Hematologic Malignancy
A Dose-escalation Study in Subjects With Advanced Malignancies
This is an open label, dose escalation study using a 3 + 3 design to determine if INCB024360 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies.
- Trial name
- NCT01195311
- Testing
- INCB024360
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Corporation
Neoplasms
A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies
The purposes of this study are to: Test the safety of DN-101 in patients with advanced malignancies Understand how fast the body absorbs, processes, and eliminates DN-101 Determine the highest dose of DN-101 that is well…
- Trial name
- NCT00055263
- Testing
- DN-101
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novacea
Solid Tumor, Adult, Refractory Tumor
A Study of DCR-STAT3 in Adults With Solid Tumors
This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.
- Trial name
- NCT06098651
- Testing
- DCR-STAT3
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Solid Tumor
A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
An Open-label, Randomized, Single-dose, Two-way Crossover Study to Compare the Bioequivalence of Senaparib 10 mg Capsules Manufactured at Different Manufacturing Sites After Administration in Fasting State in Healthy Chinese…
- Trial name
- NCT07030439
- Testing
- Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd., Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd.
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Impact Therapeutics, Inc.
Adult Solid Neoplasm, Childhood Solid Neoplasm
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide and to see how well they work in treating younger patients with tumors that have not responded to previous treatment (refractory) or…
- Conditions
- Adult Solid Neoplasm, Childhood Solid Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT02116777
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Where
- 22 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasm
A Study of SHR6390 in Advanced Solid Tumor Patients
SHR6390 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced solid tumor patients by…
- Trial name
- NCT02684266
- Testing
- SHR6390
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Evaluation of an Education Program to Increase Knowledge and Participation in Clinical Trials Among Racial/Ethnic and Rural Populations
This clinical trial evaluates a culturally tailored educational outreach intervention for increasing clinical trial knowledge, referral, and participation among racial/ethnic minority and rural populations.
- Trial name
- NCT06112002
- Testing
- Educational Intervention, Health Education, Survey Administration
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Adult Solid Tumor, Diffuse Large B Cell Lymphoma
A Phase I Trial of AZD3965 in Patients With Advanced Cancer
The main aims of this clinical study are to find out the maximum dose that can be given safely to patients, the potential side effects of the drug and how they can be managed and what happens to AZD3965 inside the body.
- Conditions
- Adult Solid Tumor, Diffuse Large B Cell Lymphoma, Burkitt Lymphoma
- Trial name
- NCT01791595
- Testing
- AZD3965
- Where
- 7 sites in United Kingdom
- Volunteers
- 53 people
- Sponsor
- Cancer Research UK
Neoplasms
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with malignancies with abnormal dependence on FGF pathway signaling.
- Trial name
- NCT01868022
- Testing
- GSK3052230, paclitaxel, carboplatin
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Cognitive/Functional Effects, Depression
Study of Physical and Mental Health of Older Patients With Newly Diagnosed Cancer
RATIONALE: Gathering information from older patients with newly diagnosed cancer may help doctors learn more about the risks of functional decline.
- Conditions
- Cognitive/Functional Effects, Depression, Hematopoietic/Lymphoid Cancer, Malnutrition
- Trial name
- NCT00769951
- Testing
- medical chart review, questionnaire administration, cognitive assessment
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Case Comprehensive Cancer Center
Neoplasms
A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors
This study examines a 96 hour infusion schedule of irinotecan alternating with 72 hour drug-free intervals in patients with solid tumors in order to determine the maximum tolerated dose of this regimen.
- Trial name
- NCT00001495
- Testing
- irinotecan (CPT-11)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms, Colorectal Neoplasms
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
This is a Phase 1 open-label study of SN2310 Injectable Emulsion in patients with advanced solid malignancies. The study is designed to determine the maximum tolerated dose and dose-limiting toxicity of SN2310 Injectable…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00385177
- Testing
- SN2310 Injectable Emulsion
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Achieve Life Sciences
Solid Pancreatic Mass Lesions, Malignant Neoplasm of Pancreas
Comparison of a Novel 22-gauge Core Biopsy Needle
The goal of this clinical research study is to compare the performance of a newly available needle with reverse bevel design (called the EchoTip® Procore™ needle) with standard needles to see which needle gives better diagnostic…
- Trial name
- NCT01598194
- Testing
- Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Solid Tumor
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune…
- Trial name
- NCT04084951
- Testing
- SQZ-PBMC-HPV, Atezolizumab, Ipilimumab
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- SQZ Biotechnologies
Advanced Solid Tumors, Lymphomas
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
This is a phase I and pharmacology study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients with Solid Tumors or Lymphoma. OBJECTIVES Primary: 1.
- Trial name
- NCT00947739
- Testing
- Camptothecin-20-O-Propionate Hydrate (CZ48)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- New Mexico Cancer Research Alliance
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.